Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Centro Nacional De Investigaciones Oncologicas (cnio)

Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos III

Carmen Blanco Aparicio

Joaquín Pastor Fernández

Sonia Martínez González

Jose Ignacio Martín Hernando

Antonio Rodríguez Hergueta

Rosario Concepción Riesco Fagundo

Ana Belén García García

Ana Isabel Hernández Higueras

David Álvaro Cebrián Muñoz

Francisco Javier Ramos Lima

Ana Maria Garcia Collazo

María Nieto Soler

David Alvaro Cebrián Muñoz

Oliver Renner

Andrés Joaquín Lopez Contreras

Carmen Varela Busto

Matilde Murga Costa

Sonsoles Rodríguez Arísteguí

María Del Rosario Rico Ferreira

Oscar Fernández-Capetillo Ruiz

Beatriz Noya Marino

Antonio Salgado Serrano

Esther Gonzalez Cantalapiedra

Carl-Gustave Pierre Saluste

Rosa María Álvarez Escobar

Cristina Ana Gómez De La Oliva

Luis Ignacio Toledo Lázaro

Antonio Cebriá Gómez

Beatriz Noya Mariño

José Ignacio MARTÍN Hernando

Rosa María ÁLvarez Escobar

David ÁLvaro CEBRIÁN MUÑOZ

Ana Belén GARCÍA GARCÍA

Elena Hernández Encinas

Esther González Cantalapiedra

María Isabel Albarrán Santiño

There is provided compounds of formula I, wherein R1, R, R, R, X, Y, Z, Rand ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds. 

Macrocyclic compounds as protein kinase inhibitors

There is provided compounds of formula (I), wherein R, R, Rand Rhave meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I). 

Tricyclic compounds for use as kinase inhibitors

Provided are chemical entities selected from compounds of formula (I), wherein R, Rand m have meanings given in the description, and pharmaceutically acceptable salts, solvates and stereoisomers thereof, which are inhibitors of ATR and are potentially useful in the treatment of cancer. Further provided are pharmaceutical compositions of the chemical entities, combination products containing the chemical entities, the use of the compositions as therapeutic agents, and methods of treatment using these compositions. 

Chemical entities

Growing community of inventors

Madrid, Spain

Carmen Blanco Aparicio